Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Tau MedicalXTAE:DRTS +2.95%6 Quick Ratio is 11.09 as of Jun. 2026, which is 7% below its 10-year median of 11.87. GuruFocus rates XTAE:DRTS with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Alpha Tau Medical ranks better than 80.48% on this metric.
Alpha Tau Medical (XTAE:DRTS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Alpha Tau Medical Quick Ratio Related Terms
Alpha Tau Medical Quick Ratio Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Tau Medical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Alpha Tau Medical's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (XTAE:DRTS) has a Quick Ratio of 11.09 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alpha Tau Medical and its competitors. This is near median its historical median of 11.87. Over the past decade, Alpha Tau Medical's Quick Ratio has ranged from 5.81 to 41.98. According to the industry distribution chart, Alpha Tau Medical ranks #275 out of 1409 companies in the Biotechnology industry, placing it in the top 19.5%.
Is Alpha Tau Medical's Quick Ratio too high?
Alpha Tau Medical's current Quick Ratio of 11.09 is near median its 10-year median of 11.87. Over the past 10 years, this metric has ranged from a low of 5.81 to a high of 41.98. The Biotechnology industry median Quick Ratio is 3.54. Alpha Tau Medical's value of 11.09 is 213.3% above this industry median. Based on the distribution chart, Alpha Tau Medical ranks #275 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alpha Tau Medical has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Quick Ratio compare to ?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #275 out of 1409 companies for Quick Ratio. This places Alpha Tau Medical in the top 20% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.54. Alpha Tau Medical's value of 11.09 is 213.3% above this benchmark. Historically, Alpha Tau Medical's own Quick Ratio has ranged from 5.81 to 41.98 over the past decade. While the company's 10-year median is 11.87 vs. the industry median of 3.54, Alpha Tau Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.54, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Tau Medical's current Quick Ratio of 11.09 is 213.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alpha Tau Medical and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Tau Medical's current Quick Ratio is 11.09, which is near median its own 10-year median of 11.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (XTAE:DRTS) has a current Quick Ratio of 11.09. The current Quick Ratio is 11.09, which is near median its 10-year median of 11.87 and 213.3% above the Biotechnology industry median of 3.54. Alpha Tau Medical's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Alpha Tau Medical (XTAE:DRTS), the current Quick Ratio is 11.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
6GF Score
Get the complete analysis for XTAE:DRTS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:DRTS has been successfully added to your 
